Bausch + Lomb to acquire Xiidra from Novartis
Bausch + Lomb has inked a deal with Novartis to acquire Xiidra (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye.
“This acquisition is a prime example of our strategy in action, as it provides needed scale for the company and transforms our pharmaceuticals business by making us a leader in ocular surface diseases,” said Brent Saunders, chairman and CEO of Bausch + Lomb. “The deal is also expected to accelerate margin expansion through a larger mix of pharmaceutical products in our portfolio, provide strong and immediate earnings accretion and presents a clear path to deleverage, making it financially compelling.”
The acquisition will complement Bausch + Lomb’s existing dry eye portfolio that includes eye and contact lens drops from the company’s consumer brand franchises and its pharmaceutical business that features Miebo (perfluorohexyloctane ophthalmic solution), which was recently approved by the Food and Drug Administration as the first and only approved eye drop for DED that directly targets tear evaporation. Xiidra and Miebo work differently to target distinct elements of the DED cycle, the company said.
[Read more: Bausch + Lomb enters pet health care space]
DED, which is one of the most common ocular surface disorders1, affects approximately 38 million people in the United States alone and approximately 739 million people worldwide. As lifestyles change and people are spending more time on digital screens, research demonstrates the overall prevalence of DED in the United States has increased in the past decade, including in younger adult patients (ages 18 to 34), the company noted.
“Dry eye disease is multi-factorial and can stem from varying root causes, which means differing treatment options are needed,” said Marguerite McDonald, of OCLI Vision in Oceanside, N.Y. “With the acquisition of Xiidra and recent approval of Miebo, Bausch + Lomb enhances its approach to different facets of dry eye and is well positioned to ensure both medicines reach as many patients as possible.”
The prescription U.S. DED field is expected to grow at a double-digit compounded annual growth rate over the next five years. Xiidra, which generated approximately $487 million in sales in 2022, is patented through 2033.
As part of the transaction, Bausch + Lomb also will acquire libvatrep (also known as SAF312), an investigational compound being studied for the treatment of chronic ocular surface pain, and AcuStream technology, an investigational device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. Libvatrep is currently in Phase 2b development with study results expected in the third quarter of 2023.
[Read more: Bausch + Lomb rolls out Enhanced PreserVision Areds 2]
Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire Xiidra, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization.
J.P. Morgan served as financial advisor to Bausch + Lomb. Wachtell, Lipton, Rosen & Katz advised on legal matters relating to the transaction, and Davis Polk & Wardwell advised on legal matters relating to the financing.